A phase 3 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Jiangsu Healthy Life Innovation Medical Technology Co., Ltd, now recruiting.
Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer is a phase 3 interventional study registered as NCT05653453 by Jiangsu Healthy Life Innovation Medical Technology Co., Ltd, with 512 participants planned, started 2022-12-20 and due to reach its primary completion in 2026-12-25. Interventions recorded: Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel and Gemcitabine hydrochloride and albumin binding paclitaxel.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/